AstraZeneca discontinues Phase 3 trial of Truqap in metastatic castration-resistant prostate cancer Ruchika Sharma30 April 2025 12:14 PM ISTTruqap was discovered by AstraZeneca subsequent to a collaboration with Astex Therapeutics.
CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal to Study anti-cancer Drug Capivasertib Dr. Divya Colin28 July 2024 6:15 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved AstraZeneca's...
AstraZeneca Truqap, Faslodex combo approved in EU for advanced ER-positive breast cancer Ruchika Sharma21 Jun 2024 10:00 AM ISTCambridge: AstraZeneca has announced that Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the...
AstraZeneca Truqap plus Faslodex recommended for approval in EU by CHMP for advanced ER-positive breast cancer Ruchika Sharma1 May 2024 11:30 AM ISTCambridge: AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the...
AstraZeneca Truqap plus Faslodex gets nod in Japan for advanced HR-positive breast cancer Ruchika Sharma31 March 2024 2:30 PM ISTCambridge: AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult...
CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal to Study Capivasertib Plus Abiraterone Dr. Divya Colin18 Feb 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
AstraZeneca gets CDSCO panel nod to study anti-cancer drug Capivasertib Dr. Divya Colin17 Dec 2023 6:00 PM ISTNew Delhi: The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Truqap plus Faslodex approved in US for advanced HR-positive breast cancer: AstraZeneca Ruchika Sharma18 Nov 2023 2:14 PM ISTCambridge: AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult...
AstraZeneca breast cancer drug combination gets USFDA okay Ruchika Sharma17 Nov 2023 11:37 AM ISTTruqap belongs to a class of drugs known as AKT inhibitors and works by targeting the AKT1 gene mutation, which is responsible for growth and...
USFDA grants priority review to Capivasertib in combination with Faslodex for advanced HR-positive breast cancer: AstraZeneca Ruchika Sharma13 Jun 2023 11:20 AM ISTBreast cancer is the most common cancer worldwide, with an estimated 2.3 million patients diagnosed each year.
Capivasertib addition to fulvestrant improves progression-free survival in patients with advanced (HR)-positive breast cancer Isra Zaman9 Dec 2022 9:45 AM ISTPatients with HR-positive, HER2-negative breast cancer are commonly treated in the first line with an endocrine therapy-such as an aromatase...
